| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nursing Homes | 52 | 2026 | 686 | 7.810 |
Why?
|
| Dementia | 20 | 2026 | 280 | 5.780 |
Why?
|
| Hospice Care | 18 | 2025 | 75 | 4.850 |
Why?
|
| Hospices | 13 | 2025 | 39 | 3.890 |
Why?
|
| Advance Care Planning | 12 | 2023 | 68 | 3.690 |
Why?
|
| Medicare | 32 | 2026 | 625 | 3.600 |
Why?
|
| Caregivers | 9 | 2026 | 294 | 3.160 |
Why?
|
| Homes for the Aged | 15 | 2026 | 166 | 2.980 |
Why?
|
| Antipsychotic Agents | 12 | 2017 | 303 | 2.560 |
Why?
|
| Practice Patterns, Physicians' | 20 | 2021 | 706 | 2.320 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 8 | 2021 | 142 | 2.100 |
Why?
|
| Aged, 80 and over | 59 | 2026 | 5614 | 1.950 |
Why?
|
| Chronic Disease | 7 | 2025 | 742 | 1.910 |
Why?
|
| Prescription Drugs | 5 | 2025 | 49 | 1.820 |
Why?
|
| Drug Prescriptions | 8 | 2025 | 164 | 1.770 |
Why?
|
| Aged | 85 | 2026 | 14965 | 1.760 |
Why?
|
| Cross-Sectional Studies | 36 | 2026 | 2701 | 1.760 |
Why?
|
| United States | 59 | 2026 | 8093 | 1.710 |
Why?
|
| Humans | 145 | 2026 | 65140 | 1.690 |
Why?
|
| Pharmaceutical Preparations | 4 | 2021 | 120 | 1.600 |
Why?
|
| Drug Monitoring | 7 | 2014 | 202 | 1.490 |
Why?
|
| Medicare Part D | 5 | 2025 | 36 | 1.460 |
Why?
|
| Polypharmacy | 5 | 2026 | 67 | 1.460 |
Why?
|
| Inappropriate Prescribing | 6 | 2019 | 68 | 1.450 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2021 | 214 | 1.450 |
Why?
|
| Health Services Misuse | 5 | 2017 | 21 | 1.440 |
Why?
|
| Palliative Care | 9 | 2023 | 249 | 1.410 |
Why?
|
| Communication | 10 | 2025 | 596 | 1.400 |
Why?
|
| Advance Directives | 3 | 2023 | 49 | 1.390 |
Why?
|
| Male | 83 | 2026 | 31047 | 1.340 |
Why?
|
| Terminal Care | 8 | 2022 | 119 | 1.330 |
Why?
|
| Deprescriptions | 4 | 2026 | 29 | 1.310 |
Why?
|
| Female | 85 | 2026 | 34018 | 1.290 |
Why?
|
| Data Collection | 3 | 2024 | 382 | 1.190 |
Why?
|
| Frail Elderly | 5 | 2022 | 114 | 1.180 |
Why?
|
| Analgesics, Opioid | 10 | 2025 | 527 | 1.070 |
Why?
|
| Physicians | 2 | 2023 | 474 | 1.030 |
Why?
|
| Geriatric Assessment | 5 | 2022 | 161 | 1.030 |
Why?
|
| Goals | 2 | 2025 | 96 | 1.000 |
Why?
|
| Family | 4 | 2022 | 245 | 0.940 |
Why?
|
| Withholding Treatment | 2 | 2017 | 38 | 0.940 |
Why?
|
| Medical Staff | 2 | 2017 | 13 | 0.920 |
Why?
|
| Independent Living | 2 | 2017 | 55 | 0.920 |
Why?
|
| Anticoagulants | 11 | 2025 | 525 | 0.900 |
Why?
|
| Decision Making | 5 | 2025 | 417 | 0.860 |
Why?
|
| Gender Identity | 2 | 2024 | 68 | 0.860 |
Why?
|
| Drug Utilization | 11 | 2021 | 204 | 0.850 |
Why?
|
| Physician-Patient Relations | 4 | 2025 | 425 | 0.840 |
Why?
|
| Sexual Behavior | 2 | 2024 | 191 | 0.810 |
Why?
|
| Practice Guidelines as Topic | 6 | 2018 | 734 | 0.760 |
Why?
|
| Drug Utilization Review | 4 | 2017 | 50 | 0.740 |
Why?
|
| Pain Management | 4 | 2017 | 174 | 0.740 |
Why?
|
| Community-Based Participatory Research | 1 | 2023 | 62 | 0.730 |
Why?
|
| Quality Assurance, Health Care | 3 | 2015 | 252 | 0.700 |
Why?
|
| Insurance Coverage | 3 | 2014 | 98 | 0.700 |
Why?
|
| Medication Systems | 2 | 2019 | 17 | 0.680 |
Why?
|
| Stress, Psychological | 2 | 2016 | 474 | 0.670 |
Why?
|
| Patient Discharge | 11 | 2022 | 519 | 0.670 |
Why?
|
| Middle Aged | 32 | 2025 | 18273 | 0.670 |
Why?
|
| Professional-Family Relations | 2 | 2024 | 91 | 0.660 |
Why?
|
| Clinical Competence | 3 | 2017 | 726 | 0.650 |
Why?
|
| Skilled Nursing Facilities | 6 | 2021 | 80 | 0.650 |
Why?
|
| Education, Nursing | 1 | 2021 | 41 | 0.640 |
Why?
|
| Patient Simulation | 1 | 2021 | 67 | 0.640 |
Why?
|
| Nurses | 2 | 2019 | 110 | 0.640 |
Why?
|
| Patient Preference | 3 | 2022 | 86 | 0.620 |
Why?
|
| Minority Groups | 2 | 2021 | 141 | 0.610 |
Why?
|
| Nurse Practitioners | 1 | 2021 | 120 | 0.610 |
Why?
|
| Warfarin | 5 | 2020 | 125 | 0.610 |
Why?
|
| Alzheimer Disease | 4 | 2024 | 765 | 0.610 |
Why?
|
| Quality of Life | 5 | 2025 | 1260 | 0.610 |
Why?
|
| Telephone | 2 | 2019 | 122 | 0.610 |
Why?
|
| Pain | 5 | 2021 | 399 | 0.590 |
Why?
|
| Perception | 2 | 2019 | 181 | 0.590 |
Why?
|
| Information Dissemination | 3 | 2016 | 113 | 0.590 |
Why?
|
| Checklist | 1 | 2019 | 71 | 0.570 |
Why?
|
| Safety Management | 2 | 2010 | 136 | 0.560 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2025 | 767 | 0.550 |
Why?
|
| Atrial Fibrillation | 6 | 2024 | 879 | 0.550 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 347 | 0.540 |
Why?
|
| Guideline Adherence | 5 | 2016 | 307 | 0.540 |
Why?
|
| Memantine | 2 | 2023 | 22 | 0.540 |
Why?
|
| Antacids | 1 | 2017 | 14 | 0.530 |
Why?
|
| Patient Compliance | 2 | 2012 | 367 | 0.530 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2008 | 17 | 0.520 |
Why?
|
| Patient-Centered Care | 4 | 2025 | 256 | 0.520 |
Why?
|
| Off-Label Use | 3 | 2015 | 14 | 0.510 |
Why?
|
| Medical Errors | 2 | 2017 | 200 | 0.510 |
Why?
|
| Clostridium Infections | 1 | 2017 | 49 | 0.500 |
Why?
|
| Quality of Health Care | 8 | 2016 | 528 | 0.500 |
Why?
|
| Electronic Health Records | 4 | 2015 | 393 | 0.500 |
Why?
|
| Referral and Consultation | 1 | 2020 | 443 | 0.500 |
Why?
|
| Peer Review | 1 | 2017 | 26 | 0.500 |
Why?
|
| Community Health Workers | 1 | 2017 | 41 | 0.500 |
Why?
|
| Inservice Training | 1 | 2017 | 85 | 0.500 |
Why?
|
| Harm Reduction | 1 | 2017 | 33 | 0.500 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 40 | 0.490 |
Why?
|
| Professional-Patient Relations | 2 | 2016 | 127 | 0.490 |
Why?
|
| Medication Errors | 4 | 2019 | 110 | 0.480 |
Why?
|
| Attitude to Death | 1 | 2016 | 19 | 0.480 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 181 | 0.470 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 805 | 0.470 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 863 | 0.470 |
Why?
|
| Communication Barriers | 2 | 2023 | 70 | 0.470 |
Why?
|
| Drug Substitution | 2 | 2019 | 40 | 0.470 |
Why?
|
| Attitude of Health Personnel | 3 | 2025 | 624 | 0.470 |
Why?
|
| Massachusetts | 8 | 2019 | 2145 | 0.470 |
Why?
|
| Spirituality | 1 | 2016 | 43 | 0.460 |
Why?
|
| Retrospective Studies | 23 | 2024 | 6872 | 0.460 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2023 | 50 | 0.460 |
Why?
|
| Medication Therapy Management | 1 | 2015 | 18 | 0.460 |
Why?
|
| Home Nursing | 1 | 2015 | 21 | 0.450 |
Why?
|
| Hypertension | 1 | 2021 | 612 | 0.450 |
Why?
|
| Mortality | 2 | 2021 | 161 | 0.450 |
Why?
|
| Frailty | 3 | 2022 | 130 | 0.450 |
Why?
|
| Health Personnel | 3 | 2019 | 384 | 0.440 |
Why?
|
| Neoplasms | 4 | 2020 | 1368 | 0.440 |
Why?
|
| Medical Futility | 1 | 2014 | 7 | 0.440 |
Why?
|
| Meditation | 1 | 2015 | 54 | 0.430 |
Why?
|
| Connecticut | 6 | 2015 | 90 | 0.430 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 81 | 0.420 |
Why?
|
| Patient Transfer | 2 | 2020 | 93 | 0.420 |
Why?
|
| Internet | 2 | 2016 | 467 | 0.420 |
Why?
|
| Consultants | 1 | 2014 | 12 | 0.420 |
Why?
|
| Nursing Staff | 2 | 2013 | 40 | 0.410 |
Why?
|
| Databases, Factual | 4 | 2026 | 883 | 0.400 |
Why?
|
| Fee-for-Service Plans | 4 | 2021 | 71 | 0.400 |
Why?
|
| Administrative Personnel | 1 | 2013 | 30 | 0.400 |
Why?
|
| Ambulatory Care Facilities | 2 | 2012 | 104 | 0.400 |
Why?
|
| Cohort Studies | 10 | 2024 | 2620 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 801 | 0.390 |
Why?
|
| Cardiovascular Agents | 2 | 2011 | 106 | 0.390 |
Why?
|
| Hospitalization | 8 | 2021 | 1392 | 0.390 |
Why?
|
| Medication Adherence | 2 | 2016 | 199 | 0.390 |
Why?
|
| Hospitals | 3 | 2020 | 387 | 0.390 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 481 | 0.390 |
Why?
|
| Sexual and Gender Minorities | 2 | 2026 | 76 | 0.380 |
Why?
|
| Stroke | 5 | 2023 | 1211 | 0.380 |
Why?
|
| Cognitive Dysfunction | 3 | 2022 | 350 | 0.380 |
Why?
|
| Drug Therapy | 1 | 2013 | 56 | 0.380 |
Why?
|
| Burnout, Professional | 1 | 2015 | 142 | 0.380 |
Why?
|
| Adult | 21 | 2025 | 17358 | 0.370 |
Why?
|
| Principle-Based Ethics | 1 | 2012 | 2 | 0.360 |
Why?
|
| Health Services Accessibility | 4 | 2022 | 591 | 0.360 |
Why?
|
| Psychiatry | 1 | 2014 | 128 | 0.360 |
Why?
|
| Surveys and Questionnaires | 9 | 2025 | 2757 | 0.360 |
Why?
|
| Myocardial Infarction | 3 | 2019 | 919 | 0.360 |
Why?
|
| Ethics, Medical | 1 | 2012 | 40 | 0.350 |
Why?
|
| Drug Labeling | 1 | 2011 | 23 | 0.350 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2010 | 140 | 0.340 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 158 | 0.340 |
Why?
|
| Organizational Culture | 1 | 2012 | 115 | 0.330 |
Why?
|
| Students, Medical | 2 | 2005 | 263 | 0.330 |
Why?
|
| Chronic Pain | 3 | 2018 | 156 | 0.330 |
Why?
|
| Prescription Fees | 2 | 2010 | 5 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2008 | 731 | 0.320 |
Why?
|
| Depression | 3 | 2026 | 900 | 0.310 |
Why?
|
| Mental Health Services | 2 | 2005 | 304 | 0.300 |
Why?
|
| Health Care Costs | 1 | 2011 | 223 | 0.300 |
Why?
|
| Physician-Nurse Relations | 1 | 2009 | 26 | 0.300 |
Why?
|
| Coronary Disease | 1 | 2010 | 246 | 0.290 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 179 | 0.280 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2008 | 63 | 0.270 |
Why?
|
| Aging | 1 | 2014 | 771 | 0.270 |
Why?
|
| Marketing | 1 | 2008 | 21 | 0.270 |
Why?
|
| Interviews as Topic | 4 | 2025 | 531 | 0.270 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 1698 | 0.270 |
Why?
|
| Life Expectancy | 3 | 2021 | 33 | 0.260 |
Why?
|
| Antidepressive Agents | 2 | 2026 | 233 | 0.260 |
Why?
|
| Pharmacists | 2 | 2023 | 130 | 0.260 |
Why?
|
| Chemoprevention | 1 | 2007 | 26 | 0.260 |
Why?
|
| Social Stigma | 2 | 2026 | 78 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2024 | 1015 | 0.250 |
Why?
|
| Documentation | 2 | 2019 | 134 | 0.250 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 1559 | 0.250 |
Why?
|
| Comorbidity | 6 | 2021 | 1119 | 0.250 |
Why?
|
| Qualitative Research | 3 | 2025 | 750 | 0.250 |
Why?
|
| Health Expenditures | 3 | 2021 | 121 | 0.240 |
Why?
|
| Continuity of Patient Care | 3 | 2014 | 174 | 0.240 |
Why?
|
| Internal Medicine | 2 | 2021 | 154 | 0.240 |
Why?
|
| Prospective Studies | 5 | 2022 | 3308 | 0.230 |
Why?
|
| Interprofessional Relations | 2 | 2024 | 137 | 0.230 |
Why?
|
| Medical Waste Disposal | 1 | 2025 | 4 | 0.230 |
Why?
|
| Age Factors | 6 | 2021 | 1586 | 0.230 |
Why?
|
| Chi-Square Distribution | 4 | 2016 | 413 | 0.220 |
Why?
|
| Patient Participation | 1 | 2007 | 234 | 0.220 |
Why?
|
| Social Discrimination | 1 | 2024 | 13 | 0.210 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 152 | 0.210 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 801 | 0.210 |
Why?
|
| Fibrinolytic Agents | 1 | 2025 | 178 | 0.210 |
Why?
|
| Medicaid | 3 | 2021 | 372 | 0.210 |
Why?
|
| Disclosure | 1 | 2024 | 57 | 0.210 |
Why?
|
| Prevalence | 6 | 2025 | 1445 | 0.210 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2024 | 70 | 0.200 |
Why?
|
| Patient Care Team | 2 | 2024 | 335 | 0.200 |
Why?
|
| Home Care Services | 1 | 2024 | 99 | 0.200 |
Why?
|
| Heart Failure | 3 | 2022 | 957 | 0.200 |
Why?
|
| Psychometrics | 1 | 2025 | 392 | 0.200 |
Why?
|
| Clinical Decision-Making | 2 | 2022 | 168 | 0.200 |
Why?
|
| Treatment Outcome | 7 | 2024 | 5792 | 0.190 |
Why?
|
| Translations | 1 | 2023 | 8 | 0.190 |
Why?
|
| Risk Factors | 8 | 2022 | 5429 | 0.190 |
Why?
|
| Health Policy | 1 | 2025 | 191 | 0.190 |
Why?
|
| New England | 3 | 2014 | 271 | 0.190 |
Why?
|
| Community-Institutional Relations | 1 | 2023 | 42 | 0.190 |
Why?
|
| Respiration, Artificial | 2 | 2016 | 298 | 0.190 |
Why?
|
| Focus Groups | 2 | 2023 | 319 | 0.190 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 38 | 0.180 |
Why?
|
| Validation Studies as Topic | 2 | 2012 | 19 | 0.180 |
Why?
|
| Universities | 1 | 2023 | 168 | 0.180 |
Why?
|
| Aftercare | 1 | 2022 | 76 | 0.170 |
Why?
|
| Ambulatory Care Information Systems | 2 | 2012 | 7 | 0.170 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 460 | 0.170 |
Why?
|
| Language | 1 | 2023 | 154 | 0.170 |
Why?
|
| Geography, Medical | 1 | 2021 | 5 | 0.170 |
Why?
|
| Cognition Disorders | 3 | 2021 | 223 | 0.170 |
Why?
|
| General Practice | 1 | 2021 | 16 | 0.170 |
Why?
|
| Cooperative Behavior | 1 | 2023 | 229 | 0.170 |
Why?
|
| Stakeholder Participation | 1 | 2021 | 29 | 0.170 |
Why?
|
| Trauma Centers | 1 | 2022 | 130 | 0.170 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 1282 | 0.170 |
Why?
|
| Activities of Daily Living | 2 | 2021 | 293 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2006 | 555 | 0.160 |
Why?
|
| Administration, Oral | 4 | 2024 | 371 | 0.160 |
Why?
|
| Cultural Competency | 1 | 2021 | 58 | 0.160 |
Why?
|
| Data Mining | 1 | 2021 | 38 | 0.160 |
Why?
|
| Patient Readmission | 2 | 2015 | 451 | 0.160 |
Why?
|
| Oregon | 4 | 2022 | 19 | 0.160 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2022 | 110 | 0.160 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2020 | 12 | 0.160 |
Why?
|
| Health Care Surveys | 3 | 2022 | 288 | 0.160 |
Why?
|
| Value-Based Purchasing | 1 | 2020 | 8 | 0.160 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2022 | 171 | 0.160 |
Why?
|
| Oxycodone | 2 | 2018 | 28 | 0.160 |
Why?
|
| Current Procedural Terminology | 1 | 2020 | 18 | 0.160 |
Why?
|
| Delphi Technique | 2 | 2021 | 112 | 0.160 |
Why?
|
| Parents | 1 | 2024 | 410 | 0.150 |
Why?
|
| Depressive Disorder | 1 | 2002 | 284 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 141 | 0.150 |
Why?
|
| Aortic Valve Stenosis | 1 | 2022 | 190 | 0.150 |
Why?
|
| Medical Overuse | 1 | 2019 | 15 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 407 | 0.150 |
Why?
|
| Laxatives | 1 | 2019 | 3 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 740 | 0.150 |
Why?
|
| Recurrence | 2 | 2017 | 657 | 0.140 |
Why?
|
| Rivaroxaban | 1 | 2018 | 19 | 0.140 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 66 | 0.140 |
Why?
|
| Geographic Mapping | 1 | 2018 | 8 | 0.140 |
Why?
|
| Dabigatran | 1 | 2018 | 20 | 0.140 |
Why?
|
| Machine Learning | 1 | 2021 | 195 | 0.140 |
Why?
|
| Sex Factors | 2 | 2012 | 992 | 0.140 |
Why?
|
| Blood Pressure | 1 | 2021 | 526 | 0.140 |
Why?
|
| Curriculum | 2 | 2025 | 608 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 1222 | 0.140 |
Why?
|
| Adolescent | 5 | 2022 | 6297 | 0.140 |
Why?
|
| Internship and Residency | 1 | 2025 | 800 | 0.130 |
Why?
|
| Family Practice | 2 | 2012 | 215 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2014 | 754 | 0.130 |
Why?
|
| Psychomotor Agitation | 1 | 2017 | 20 | 0.130 |
Why?
|
| Fractures, Bone | 1 | 2018 | 138 | 0.130 |
Why?
|
| Pneumonia | 1 | 2020 | 291 | 0.130 |
Why?
|
| Global Health | 2 | 2019 | 181 | 0.130 |
Why?
|
| Health Status | 2 | 2017 | 447 | 0.130 |
Why?
|
| Health Planning | 1 | 2017 | 32 | 0.130 |
Why?
|
| Wisconsin | 1 | 2016 | 17 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 856 | 0.130 |
Why?
|
| Primary Health Care | 2 | 2014 | 721 | 0.130 |
Why?
|
| Length of Stay | 1 | 2020 | 828 | 0.130 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 431 | 0.130 |
Why?
|
| Software Design | 1 | 2016 | 28 | 0.130 |
Why?
|
| Organizational Case Studies | 1 | 2016 | 41 | 0.130 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 57 | 0.130 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2017 | 33 | 0.130 |
Why?
|
| Staff Development | 1 | 2017 | 58 | 0.120 |
Why?
|
| Skin Diseases, Infectious | 1 | 2016 | 12 | 0.120 |
Why?
|
| Third-Party Consent | 1 | 2016 | 9 | 0.120 |
Why?
|
| Behavior Control | 1 | 2016 | 15 | 0.120 |
Why?
|
| Urban Population | 2 | 2015 | 200 | 0.120 |
Why?
|
| Analgesics | 1 | 2017 | 102 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 159 | 0.120 |
Why?
|
| Anxiety | 2 | 2020 | 426 | 0.120 |
Why?
|
| Algorithms | 2 | 2012 | 1050 | 0.120 |
Why?
|
| Health Education | 1 | 2017 | 189 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2016 | 208 | 0.120 |
Why?
|
| Morphine | 1 | 2016 | 60 | 0.120 |
Why?
|
| Psychology | 1 | 2016 | 45 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2017 | 230 | 0.120 |
Why?
|
| Soft Tissue Infections | 1 | 2016 | 48 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2016 | 576 | 0.120 |
Why?
|
| Ischemic Attack, Transient | 2 | 2018 | 96 | 0.120 |
Why?
|
| Fentanyl | 1 | 2016 | 66 | 0.120 |
Why?
|
| Patients | 1 | 2017 | 115 | 0.120 |
Why?
|
| International Normalized Ratio | 2 | 2012 | 36 | 0.110 |
Why?
|
| Half-Life | 1 | 2015 | 81 | 0.110 |
Why?
|
| Outpatients | 1 | 2016 | 143 | 0.110 |
Why?
|
| Transitional Care | 1 | 2015 | 32 | 0.110 |
Why?
|
| Poisson Distribution | 2 | 2012 | 52 | 0.110 |
Why?
|
| Publication Bias | 1 | 2015 | 21 | 0.110 |
Why?
|
| Rationalization | 1 | 2015 | 4 | 0.110 |
Why?
|
| Medical Informatics | 1 | 2015 | 72 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2019 | 418 | 0.110 |
Why?
|
| Leadership | 1 | 2017 | 211 | 0.110 |
Why?
|
| Consensus | 1 | 2016 | 176 | 0.110 |
Why?
|
| Marketing of Health Services | 1 | 2015 | 22 | 0.110 |
Why?
|
| Mental Status Schedule | 1 | 2014 | 20 | 0.110 |
Why?
|
| Hemorrhage | 3 | 2024 | 286 | 0.110 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 253 | 0.110 |
Why?
|
| Office Visits | 1 | 2014 | 48 | 0.100 |
Why?
|
| Medical Records | 2 | 2019 | 140 | 0.100 |
Why?
|
| Disease Progression | 2 | 2016 | 1220 | 0.100 |
Why?
|
| Young Adult | 3 | 2020 | 4809 | 0.100 |
Why?
|
| Critical Illness | 1 | 2016 | 330 | 0.100 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 84 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2021 | 496 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2013 | 201 | 0.090 |
Why?
|
| Value of Life | 1 | 2012 | 1 | 0.090 |
Why?
|
| Moral Obligations | 1 | 2012 | 7 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 602 | 0.090 |
Why?
|
| Ethical Analysis | 1 | 2011 | 3 | 0.090 |
Why?
|
| Health Transition | 1 | 2011 | 5 | 0.090 |
Why?
|
| Pain Measurement | 3 | 2018 | 342 | 0.090 |
Why?
|
| Fees, Pharmaceutical | 1 | 2011 | 5 | 0.090 |
Why?
|
| Financing, Personal | 1 | 2011 | 23 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2014 | 317 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2012 | 497 | 0.090 |
Why?
|
| Physical Examination | 2 | 2022 | 109 | 0.090 |
Why?
|
| Economic Competition | 1 | 2010 | 6 | 0.080 |
Why?
|
| Community Pharmacy Services | 1 | 2010 | 12 | 0.080 |
Why?
|
| Drugs, Generic | 1 | 2010 | 19 | 0.080 |
Why?
|
| Forecasting | 1 | 2011 | 230 | 0.080 |
Why?
|
| Medical Order Entry Systems | 1 | 2010 | 42 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2024 | 587 | 0.080 |
Why?
|
| Emergency Service, Hospital | 2 | 2016 | 1149 | 0.080 |
Why?
|
| Hypolipidemic Agents | 1 | 2010 | 25 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2011 | 137 | 0.080 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2010 | 73 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 460 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 2483 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 286 | 0.070 |
Why?
|
| Insurance, Medigap | 1 | 2008 | 1 | 0.070 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2008 | 14 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 325 | 0.070 |
Why?
|
| Logistic Models | 2 | 2016 | 1269 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 463 | 0.070 |
Why?
|
| Medical Indigency | 1 | 2008 | 6 | 0.070 |
Why?
|
| Homosexuality, Female | 1 | 2008 | 22 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2008 | 58 | 0.070 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2008 | 48 | 0.070 |
Why?
|
| Drug Costs | 1 | 2008 | 55 | 0.070 |
Why?
|
| Tramadol | 2 | 2018 | 14 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2007 | 18 | 0.070 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2007 | 19 | 0.070 |
Why?
|
| Tamoxifen | 1 | 2007 | 42 | 0.060 |
Why?
|
| Time Factors | 3 | 2019 | 3762 | 0.060 |
Why?
|
| Delayed-Action Preparations | 2 | 2018 | 120 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2007 | 124 | 0.060 |
Why?
|
| Specialization | 1 | 2007 | 82 | 0.060 |
Why?
|
| Medicine | 1 | 2007 | 53 | 0.060 |
Why?
|
| Age Distribution | 2 | 2017 | 262 | 0.060 |
Why?
|
| Long-Term Care | 2 | 2017 | 179 | 0.060 |
Why?
|
| Medication Reconciliation | 1 | 2025 | 14 | 0.060 |
Why?
|
| Women's Health | 1 | 2008 | 374 | 0.060 |
Why?
|
| Health Facility Size | 2 | 2015 | 16 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 1419 | 0.050 |
Why?
|
| Nurse Administrators | 1 | 2024 | 18 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2008 | 542 | 0.050 |
Why?
|
| Health Behavior | 1 | 2008 | 484 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2024 | 46 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2005 | 102 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2025 | 235 | 0.050 |
Why?
|
| Confidentiality | 1 | 2002 | 58 | 0.050 |
Why?
|
| Self Report | 2 | 2016 | 390 | 0.050 |
Why?
|
| Injury Severity Score | 1 | 2022 | 117 | 0.040 |
Why?
|
| Religion | 1 | 2022 | 35 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 930 | 0.040 |
Why?
|
| Mentors | 1 | 2022 | 118 | 0.040 |
Why?
|
| Death | 1 | 2021 | 33 | 0.040 |
Why?
|
| Health Surveys | 1 | 2002 | 316 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2022 | 181 | 0.040 |
Why?
|
| Interdisciplinary Studies | 1 | 2020 | 7 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2022 | 296 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 508 | 0.040 |
Why?
|
| International Classification of Diseases | 2 | 2012 | 136 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 1693 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 1113 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 306 | 0.030 |
Why?
|
| Propensity Score | 1 | 2019 | 190 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2024 | 2061 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 69 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2018 | 74 | 0.030 |
Why?
|
| Emotions | 1 | 2020 | 233 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2018 | 165 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 374 | 0.030 |
Why?
|
| Georgia | 1 | 2017 | 90 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 897 | 0.030 |
Why?
|
| New Hampshire | 1 | 2017 | 43 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2018 | 128 | 0.030 |
Why?
|
| Paracentesis | 1 | 2016 | 12 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2021 | 875 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 252 | 0.030 |
Why?
|
| Oxymorphone | 1 | 2016 | 5 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 31 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 68 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2016 | 159 | 0.030 |
Why?
|
| Rhode Island | 1 | 2016 | 110 | 0.030 |
Why?
|
| Program Development | 1 | 2017 | 208 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 493 | 0.030 |
Why?
|
| Child | 1 | 2024 | 4607 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 261 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2021 | 1326 | 0.030 |
Why?
|
| Buprenorphine | 1 | 2016 | 198 | 0.020 |
Why?
|
| Health Services Research | 1 | 2014 | 265 | 0.020 |
Why?
|
| Pharmacies | 1 | 2013 | 36 | 0.020 |
Why?
|
| Occult Blood | 1 | 2012 | 19 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2012 | 65 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 1784 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 75 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 236 | 0.020 |
Why?
|
| Colonoscopy | 1 | 2012 | 97 | 0.020 |
Why?
|
| Reminder Systems | 1 | 2010 | 75 | 0.020 |
Why?
|
| Income | 1 | 2010 | 169 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1163 | 0.020 |
Why?
|
| Phenytoin | 1 | 2008 | 15 | 0.020 |
Why?
|
| Digoxin | 1 | 2008 | 23 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 2008 | 14 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2008 | 66 | 0.020 |
Why?
|
| Women's Health Services | 1 | 2008 | 30 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2008 | 104 | 0.020 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2008 | 102 | 0.020 |
Why?
|